These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Re: chemical structure and stability of gadolinium chelates. Idée JM; Port M; Corot C Radiographics; 2009 Nov; 29(7):2099. PubMed ID: 19926764 [No Abstract] [Full Text] [Related]
4. Nephrogenic systemic fibrosis and gadolinium: a cautionary tale in the molecular imaging era. Wang SC J Med Imaging Radiat Oncol; 2008 Aug; 52(4):305-6. PubMed ID: 18811752 [No Abstract] [Full Text] [Related]
10. MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety. Juluru K; Vogel-Claussen J; Macura KJ; Kamel IR; Steever A; Bluemke DA Radiographics; 2009; 29(1):9-22. PubMed ID: 19019996 [TBL] [Abstract][Full Text] [Related]
11. Nephrogenic systemic fibrosis: possible mechanisms and imaging management strategies. Dawson P J Magn Reson Imaging; 2008 Oct; 28(4):797-804. PubMed ID: 18821621 [No Abstract] [Full Text] [Related]
12. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis. Abraham JL; Edward M AJR Am J Roentgenol; 2009 Oct; 193(4):W354; author reply W355. PubMed ID: 19770307 [No Abstract] [Full Text] [Related]
13. Nephrogenic systemic fibrosis: the need for accurate case reporting. Spinazzi A; Kirchin MA; Pirovano G J Magn Reson Imaging; 2009 May; 29(5):1240; author reply 1241. PubMed ID: 19388104 [No Abstract] [Full Text] [Related]
14. Nephrogenic systemic fibrosis: is gadolinium to be blamed? Jikki PN J Assoc Physicians India; 2008 Nov; 56():915-6. PubMed ID: 19263697 [No Abstract] [Full Text] [Related]
15. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned? Weinreb JC; Abu-Alfa AK J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035 [TBL] [Abstract][Full Text] [Related]
16. Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis. Heverhagen JT; Krombach GA; Gizewski E Rofo; 2014 Jul; 186(7):661-9. PubMed ID: 24477507 [TBL] [Abstract][Full Text] [Related]
17. NSF prevention in clinical practice: summary of recommendations and guidelines in the United States, Canada, and Europe. Leiner T; Kucharczyk W J Magn Reson Imaging; 2009 Dec; 30(6):1357-63. PubMed ID: 19937935 [TBL] [Abstract][Full Text] [Related]
18. Nephrogenic systemic fibrosis and management of high-risk patients. Altun E; Semelka RC; Cakit C Acad Radiol; 2009 Jul; 16(7):897-905. PubMed ID: 19375360 [TBL] [Abstract][Full Text] [Related]
19. Gadolinium-associated nephrogenic systemic fibrosis in patients with renal failure: the need for an interdisciplinary helping network. Stratta P; Canavese C; Quaglia M; Fenoglio R Rheumatology (Oxford); 2010 Apr; 49(4):821-3. PubMed ID: 20032228 [No Abstract] [Full Text] [Related]
20. [Causal relationship between the use of gadolinium based contrast media and nephrogenic systemic fibrosis]. Varela CU; Prieto-Rayo JC Rev Med Chil; 2014 Dec; 142(12):1565-74. PubMed ID: 25693439 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]